BRUKER CORP (BRKRP)

Current Report Filed: 2026-05-15

Bruker Corporation declared a quarterly cash dividend of $0.05 per share on common stock, payable July 7, 2026, indicating management confidence in cash flow generation and shareholder return capacity.
The dividend declaration represents a routine quarterly action filed under Item 8.01 (Other Events), suggesting no material corporate developments or strategic changes announced in this period.
The filing covers both common stock (BRKR) and 6.375% Mandatory Convertible Preferred Stock Series A (BRKRP), indicating the company maintains a diversified capital structure with multiple equity instruments.
Signed by Thomas M. Bures, Chief Accounting Officer, confirming proper authorization and governance procedures for dividend declaration.

Quarterly Report Filed: 2026-05-07

The filing shows Q1 2026 results with multiple operating segments including BSI Nano, BSI Calid, BSI Biospin, Energy and Superconducting Technologies, and Tofwerk, indicating a diversified portfolio structure across scientific instrumentation markets.
Significant restructuring activities are evident with severance and termination charges related to BSI Nano and corporate-wide restructuring plans, suggesting management is actively optimizing cost structure and organizational efficiency.
The company maintains complex derivative instruments including cross-currency swaps, interest rate swaps, and foreign exchange forwards, indicating active management of currency and interest rate exposure across international operations.
Multiple note purchase agreements and term loans across different currencies (EUR, CHF) demonstrate reliance on debt financing, with maturities ranging from 2029 to 2036 requiring careful cash flow management.

Current Report Filed: 2026-05-06

Bruker Corporation announced Q1 2026 financial results on May 6, 2026, with the press release containing forward-looking statements that indicate management's confidence in future performance.
The company has both common stock (BRKR) and mandatory convertible preferred stock (BRKRP) trading on Nasdaq, indicating a capital structure with preferred equity holders having specific conversion rights and dividend obligations at 6.375%.
The 8-K filing is limited to earnings announcement and does not disclose material agreements, executive changes, or significant corporate events, suggesting this is a routine quarterly earnings report with no major developments.

Current Report Filed: 2026-04-28

Bruker declared a quarterly dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A, payable June 1, 2026, indicating the company continues to service its preferred equity obligations on schedule.
This is a routine dividend declaration on preferred stock, suggesting stable operations and continued capital allocation to preferred shareholders without material business impact.
The filing contains no material business developments, strategic announcements, or material events beyond the routine preferred dividend declaration, representing standard ongoing corporate governance.

Insider Trading Filed: 2026-04-16

The reporting person, Mark Munch, exercised 2,000 stock options at $22.19 and sold 2,000 shares of Bruker Corp common stock at $39.90, indicating insider selling activity.
The sale was executed pursuant to a Rule 10b5-1 trading plan, suggesting the transaction was pre-planned and not based on material non-public information.
The reporting person currently holds 128,443 shares of Bruker Corp common stock directly, representing a decrease from the previous holding of 130,443 shares.

Current Report Filed: 2026-04-10

Bruker Corporation announced the departure of Falko Busse, Ph.D., an executive officer and President of the Bruker BioSpin Group, effective October 31, 2026. The company has agreed to provide separation benefits including severance, bonus, and vacation payout totaling approximately $1,020,351.
The departure of a key executive could signal changes in the company's leadership or business strategy, which may impact investor sentiment and the stock price.
The company will need to find a suitable replacement for the Bruker BioSpin Group president role, which could affect the division's operations and performance.

Current Report Filed: 2026-04-01

Bruker Corporation has appointed Thierry L. Bernard, the current CEO and Managing Director of QIAGEN N.V., to its Board of Directors, effective April 1, 2026.
Mr. Bernard has over 15 years of experience in the biotech and diagnostics industry, including senior leadership roles at bioMérieux SA and QIAGEN.
The addition of Mr. Bernard to the Board suggests Bruker may be looking to leverage his industry expertise and connections to drive growth and strategic initiatives.

Insider Trading Filed: 2026-03-16

Insider Mark Munch sold 2,000 shares of Bruker Corp. stock at a price of $35.44 per share, reducing his direct ownership to 128,443 shares.
Munch also exercised 2,000 stock options with an exercise price of $22.19, increasing his holdings.
The stock sales were made pursuant to a 10b5-1 trading plan, which suggests pre-planned transactions rather than opportunistic trading.

Annual Report Filed: 2026-02-27

Bruker Corp reported a significant gain on a business combination in 2025, indicating the company made strategic acquisitions to expand its operations.
The company's cost of revenue increased year-over-year, which may impact profitability and margins if not offset by higher sales.
Bruker has substantial long-term debt, with upcoming maturities in 2027 and 2031, which could strain its financial resources if not managed properly.

Current Report Filed: 2026-02-20